Jaguar health's executive vp dr. karen brunke joins bio's rare disease and orphan drugs committee

Jaguar is supporting investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of short bowel syndrome and microvillus inclusion disease in the us, eu, and middle east/north africa regions, with results expected before the end of 2023 and in 2024 dr. brunke to present at the october 30-november 2, 2023 world orphan drug congress in barcelona and the november 6-8, 2023 bio-europe® conference in munich san francisco, ca / accesswire / september 7, 2023 / jaguar health, inc. (nasdaq:jagx), a commercial-stage pharmaceuticals company developing first-in-class plant-based gastrointestinal (gi) prescription medicines, today announced that karen brunke, phd, the company's evp of corporate and business development, has become a member of the biotechnology innovation organization's (bio) rare disease and orphan drugs committee. bio is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the united states and in more than 30 other nations.
JAGX Ratings Summary
JAGX Quant Ranking